Vischer in the acquisition of Evitria Group by Atlas Antibodies

Atlas Antibodies, a global developer of advanced reagents for biomedical research based in Sweden, has agreed to acquire Evitria Group from its shareholders. The transaction closed on August 5, 2021.

Vischer advised the sellers on this transaction. The team, headed by partner Jürg Luginbühl (corporate/ m&a, pictured) partner Marc Ph. Prinz (labor law), partner Adrian Dörig (banking/finance), partner Stefan Kohler (ip/regulatory), senior associate Christian Schneiter (banking/finance), senior associate Sebastian Weber (corporate/m&a), associate Flavio Langenegger (corporate/m&a) and Gordana Nisevic (corporate/m&a).

Founded in 2010 in Zurich, Switzerland, The Evitria Group is a global company specializing in the field of transient expression of antibodies in CHO cells with an international customer portfolio of leading biopharmaceutical companies in therapeutic and diagnostic antibody research.